FGFR3 Rabbit Polyclonal Antibody

CAT#: TA325462

Rabbit Polyclonal FGFR3 Antibody

Product Images

Western blot analysis on LOVO cell lysate using FGFR3 Antibody

• 

  Immunohistochemical analysis of paraffin-embedded breast carcinoma tissue using FGFR3 Antibody.

Specifications

Product Data

• Applications: IHC, WB
• Recommended Dilution: WB: 1:500-1:2000; IHC: 1:50-1:200
• Reactivities: Human, Mouse, Rat
• Host: Rabbit
• Isotype: IgG
• Clonality: Polyclonal
• Immunogen: The antiserum was produced against a synthesized A synthesized peptide derived from human FGFR3.
• Formulation: Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
• Concentration: lot specific
• Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific peptide.
• Conjugation: Unconjugated
• Storage: Store at -20°C as received.
• Stability: Stable for 12 months from date of receipt.
• Gene Name: fibroblast growth factor receptor 3
• Database Link:
  NP_000133
  Entrez Gene 14184 MouseEntrez Gene 84489 RatEntrez Gene 2261 Human
  UniProt ID P22607
• Background: FGFR3 a receptor tyrosine kinase of the highly-conserved FGFR family that binds fibroblast growth factor (FGF). Mutations are associated with thanatophoric dysplasia (TD), craniosynostosis Adelaide type, many craniosynostotic syndromes and bone malformations. Three splice-variant isoforms have been described. Activating point mutations cause dwarfism, including achondroplasia, hypochrondroplasia and thanatophoric dysplasia, and facial and other morphogenetic disorders, including Crouzon syndrome, craniosynostosis Adelaide type, San Diego skeletal displasia and Muenke syndrome. Translocations t(4;14) involving the IgH region are common in multiple myeloma and frequently involve FGFR3.
• Synonyms: ACH; CD333; CEK2; HSFGFR3EX; JTK4

Reference Data

• Protein Families: Druggable Genome, Protein Kinase, Transmembrane
• Protein Pathways: Bladder cancer, Endocytosis, MAPK signaling pathway, Pathways in cancer, Regulation of actin cytoskeleton